SAMBA HIV-1 Semi-quantitative whole blood test for resource limited settings

Information

  • Research Project
  • 9142023
  • ApplicationId
    9142023
  • Core Project Number
    R44AI097120
  • Full Project Number
    2R44AI097120-05
  • Serial Number
    097120
  • FOA Number
    PA-15-269
  • Sub Project Id
  • Project Start Date
    8/3/2011 - 12 years ago
  • Project End Date
    7/31/2018 - 5 years ago
  • Program Officer Name
    FITZGIBBON, JOSEPH E.
  • Budget Start Date
    8/15/2016 - 7 years ago
  • Budget End Date
    7/31/2017 - 6 years ago
  • Fiscal Year
    2016
  • Support Year
    05
  • Suffix
  • Award Notice Date
    8/11/2016 - 7 years ago

SAMBA HIV-1 Semi-quantitative whole blood test for resource limited settings

? DESCRIPTION (provided by applicant): The ultimate aim of this project is to develop diagnostic platform for viral load monitoring using whole blood samples of HIV-1 infected patients in point-of-care (POC) and resource-limited settings to be submitted for WHO prequalification and/or CE-marking. Estimation of viral load in HIV-1 patients receiving anti-viral treatment (ART) is considered the best marker for monitoring the efficacy ART, identifying and discriminating non-compliance and resistance. Currently all viral load tests are performed from plasma samples since using whole blood gives an overestimation of the viral load due to amplification of integrated HIV DNA in nucleated white blood cells. Diagnostics for the Real World (DRW) has developed the SAMBA HIV-1 Whole Blood Semi-quantitative Test (SAMBA-WBSQ) for use at POC and in resource-limited setting during Phase I. SAMBA-WBSQ uses leukodepletion to remove the nucleated cells and can distinguish between patients with viral loads above or below a predetermined clinically relevant cut-off, of 1,000 copies/ml, to aid clinicians to monitor non- compliance, treatment efficacy or treatment failure due to the development of resistance. This proposal is to further develop and optimize the SAMBA-WBSQ assay for regulatory submission to WHO prequalification and/or CE-marking.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    951508
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:951508\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DIAGNOSTICS FOR THE REAL WORLD, LTD
  • Organization Department
  • Organization DUNS
    141057898
  • Organization City
    SUNNYVALE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940852919
  • Organization District
    UNITED STATES